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ABSTRACT
Natural products, and molecules derived from them, have played an extremely
large role in the field of medicine and have contributed as therapies for numerous disease
states. Unfortunately, the rate of discovery of medically relevant molecules from natural
sources is slowing as secondary metabolite studies from microbes are increasingly
yielding the re-isolation of previously known compounds.

This study focused on

isolating new secondary metabolites through the usage of two different techniques: (1)
treatment of fungi and bacteria with epigenetic modifying compounds to induce natural
product production, and (2) genome mining/bioinformatic analysis of natural product
gene clusters to enhance the isolation of new compounds from previously uninvestigated
species. Previous studies in the literature have shown treatment with chemical epigenetic
modifiers to be successful in inducing new secondary metabolite production in fungi. At
the start of my research, no natural product studies involving epigenetic modifiers had
been performed in bacteria, and, to date, only one publication has appeared in the peerreviewed literature. The approach used during my investigation was to induce new
metabolite formation in the bacterium Bacillus pumilus strain RI06-95 via epigenetic
modification using agents that target several epigenetic regulatory mechanisms.
Reproducibility proved a difficulty as treatment of the same organism induced the
production of different metabolites in repeat experiments.
The second focus of this study utilized genome mining and bioinformatic analysis
of natural product gene clusters in order to isolate new secondary metabolites from
organisms previously unstudied for natural product synthesis. The Secondary Metabolite
Online Repository (SMOR) is a new tool that rapidly analyzes the well-curated complete

microbial genome sequences located on the National Center for Biotechnology
Information Genome Database and flags natural product gene clusters. Many organisms
are sequenced for reasons other than determination of their biosynthetic potential, and
thus have been largely overlooked for their secondary metabolite production. By using
SMOR and other bioinformatic tools, this study sought to isolate natural products,
particularly predicted cyclic lipopeptide antibiotics, from the potentially overlooked
microorganism Bradyrhizobium sp. BTAi1. Extract fractions showed bioactivity against
methicillin resistant Staphylococcus aureus and structural characterization of a purified
bioactive molecule indicated the potential presence of one of the predicted cyclic
lipopeptides.

Unfortunately due to insufficient material and long culturing times,

structural elucidation of the bioactive molecules was not possible.
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CHAPTER 1:
EPIGENETIC MODIFICATION TO ACCESS
CRYPTIC NATURAL PRODUCT GENE CLUSTERS

1

INTRODUCTION
Genome mining uses bioinformatic analyses to identify genetic sequences in an
organism responsible for desired functions. This technique has gained use in the field of
natural products, and allows researchers to search through an organism’s genome to
identify gene clusters that may encode enzymes that produce secondary metabolites (Lim,
2012; Medema 2011). These techniques also allow researchers to predict the potential
structure of the natural product encoded by the gene cluster.

Unfortunately, many

compounds that are predicted in the genome are not expressed under normal cultivation
conditions and cannot be isolated (Hertweck, 2009). These genes are commonly referred
to as cryptic or silent gene clusters and have been found to be prevalent in microbial
genomes. The genome for the fungus Aspergillus niger contains thirty-one polyketide
synthase gene clusters, fifteen non-ribosomal peptide synthase gene clusters, and nine
hybrid clusters. Of the identified clusters less than 30% of the corresponding molecules
were isolated under normal laboratory conditions while the remaining 70% of potential
metabolites remained elusive (Fisch, 2009). In order to gain access to these cryptic gene
clusters, researchers are now utilizing a variety of techniques such as co-culturing,
ribosomal engineering, alteration of promoter regions and transcription factors, and
alteration of growth conditions (Chiang, 2011). Another technique which has shown
promising results is the induction of epigenetic modifications through chemical and
genetic knockout methods. Upon treatment of Aspergillus niger with the epigenetic
modifying compound suberohydroxamic acid, forty-eight of the previously mentioned
fifty-five gene clusters were found to be up-regulated by qRT-PCR (Fisch, 2009).
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Epigenetics is the change in gene expression caused by mechanisms other than the
underlying DNA sequence. The epigenome differs from the genome by accounting for
gene expression levels under varying conditions. Most of the mechanisms which induce
epigenetic change function by altering how DNA is stored by adding additional
molecular units to DNA or to histones. Histones contain many positively charged lysine
tails which can act as attachment points for molecules such as acetyl groups (Grunstein,
1997), phosphates (Hammet, 2007), ubiquitin (Geng, 2008), and biotin (Hassan, 2006).
By altering the histone structure through these modifications, the transcription of the
DNA surrounding the histone can be affected. Acetylation of a histone decreases its
positive charge density. Therefore, the electrostatic interactions between the positively
charged histone and negatively charged DNA are decreased. This affects how tightly the
DNA binds to the histone, and relaxes the chromatin structure. The relaxed chromatin
structure is more accessible to replicative enzymes allowing for the increased
transcription of the previously down-regulated genes (Grunstein, 1997).
By altering the expression or functionality of epigenetic regulatory enzymes
through inhibitory compounds or gene knockout, researchers can induce the production
of new natural products. Research groups have already demonstrated these techniques
for the isolation of novel compounds (Williams, 2008; Asai, 2012; Fisch, 2009; Beau,
2012). A trend can be seen when amongst the types of molecules produced in response
to these treatments; most are either antibiotics or toxins.

Therefore, using these

techniques may lead to the isolation of molecules with clinically important bioactivity.
With the diminishing amount of effective antibiotics due to resistance, the discovery of
new antimicrobial agents is of extreme importance.
3

Fungi have been the primary focus for research involving the use of epigenetic
modification to access cryptic natural product gene clusters. No identified publications at
the start of my research had studied the use of epigenetic modification in bacterial natural
product isolation. To date, only one paper was published in which bacteria were treated
with epigenetic modifying compounds to elicit metabolite production (Wang, 2013).
Bacteria do not have histones so many of the targets and enzymes that researchers alter in
fungi to induce epigenetic change do not exist in bacteria. That is not to say that bacteria
do not have their own epigenetic regulatory mechanisms. Currently, the best understood
method which bacteria use to alter their epigenome is the methylation of DNA
(Casadesús, 2006).

Different DNA methyltransferases (DNMT) target unique DNA

sequences at which they attach methyl groups on cytosine bases. Methylation near gene
promoter regions causes variations in gene expression (Suzuki, 2008). It may therefore
be possible to access silent natural product gene clusters in bacteria through treatment
with drugs such as 5-azacytidine and procaine which inhibit DNMT. With DNMT
inhibition reducing overall methylation of DNA, regulatory proteins may interact better
with gene promoter regions in a natural product cluster and increase gene expression. By
expanding the use of these techniques to bacteria, it may be possible to gain access to an
untapped pool of compounds encoded for by silent bacterial natural product gene
clusters. Therefore, this study explored the treatment of bacteria as well as fungi with
epigenetic modifying compounds with the overarching aim of isolating new natural
products.
The bacteria used in this study was a strain of Bacillus pumilus isolated from a
sponge found in the Pettaquamscutt River in Narragansett, RI. This strain, known as
4

RI06-95, was previously studied by our lab at which time its genome was sequenced.
RI06-95 was chosen to be treated with epigenetic modifying compounds as any
metabolites isolated in response to the treatment could then ideally be associated back to
their respective gene clusters. Several fungi were also chosen to be treated during this
study. These fungi were isolated from sediment samples taken from the South Pacific
Gyre during expedition 329 of the Integrated Ocean Drilling Program (Expedition 329
Scientists, 2011). The isolated fungi were already under study for the production of
secondary metabolites in our lab and were included in this study in order to increase the
potential number of bioactive molecules isolated.
METHODS
Selection of Epigenetic Modifying Compounds and MIC Determination
The epigenetic modifiers (EM) used during this study were selected based on
previous studies reported in the literature with fungi (Cichewicz, 2010). Selection was
also influenced by the mechanism of action of each EM in order to test the alteration of
the epigenome by a wide array of mechanisms. The EMs 5-azacytidine, levofloxacin,
prednisone, procaine, suberohydroxamic acid, and trimethoprim were chosen (See Table
1 for list of EMs used and their respective mechanisms of action).
Epigenetic Modifying Compound Mechanism of Action
DNA Methyltransferase inhibitor, Histone
5-Azacytidine
Methyltransferase inhibitor
Levofloxacin
DNA Gyrase and Topoisomerase IV inhbitor
Prednisone
Increases Histone Deacetylation activity
Procaine
DNA Methyltransferase inhibitor
Suberohydroxamic Acid
Histone Deacetylase Inhibitor
Trimethoprim
Dihydrofolate reductase inhibitor
Table 1: EMs utilized and their respective mechanisms of action.
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The minimum inhibitory concentration (MIC) of each EM to each organism was
determined prior to the treatment of cultures. MICs were identified via a 10x broth
dilution series with the highest concentration at 10mM. The broth dilution series were
performed in 96 well plates containing YPM media (0.2% yeast extract, 0.2% peptone,
0.4% mannitol, 3.5% Instant Ocean® by Marineland) for fungi and YP media (0.2%
yeast extract, 0.2% peptone, 3.5% Instant Ocean® by Marineland) for RI06-95.
Organisms and EM were added on the same day and incubated at 30°C for 4 to 7 days
while rotating at 200 RPM. The MIC of each organism to each EM was determined by
visual inspection. As two EM stock solutions (trimethoprim and prednisone) could only
dissolve in DMSO, a 10x broth dilution series was also performed using DMSO with the
highest concentration of DMSO at 10% of total volume.
Culturing with Epigenetic Modifying Compounds
RI06-95 was plated on 2% YP agar petri dish. One sterile colony-forming unit
was scraped with a sterile pipet tip and dropped into 10 mL of YP media. After 4 days,
25 µL of bacterial culture was transferred into a centrifuge tube containing 25 mL YP
media. Cultures were then grown at 30°C at 200 RPM for 18 hours at which time each
EM was added into separate tubes (See Table 2 for the list of concentrations used for
each EM). Cultures were grown in the same conditions for 4 more days and then were
frozen. Four 1 liter cultures of RI06-95 were also created in YP medium at 30°C shaking
at 150 RPM for 5 days. Trimethoprim was added on day 2 of culturing. Fungal cultures
were created by directly adding 50 µL of thawed spores to 25 mL YPM in centrifuge
tubes and grown at 30°C shaking at 200 RPM. After 24 hours each EM was added to
separate tubes and cultures were continued for 6 more days and then frozen (See Table
6

2). Concentrations of EM used were chosen based upon MIC data; one concentration
was a tenth the MIC and the second was variable depending on morphological changes
observed during MIC testing. The concentration of one tenth the MIC was selected based
on studies with fungi previously reported in the literature

(Cichewicz, 2010).

If

morphological changes were seen at higher EM concentrations in some organisms during
MIC testing then a second EM concentration up to a half of the MIC would be used
during treatment in hopes that morphological changes would correlate to changes in
natural product chemistry. Untreated cells were also cultured as a control.
Epigenetic Modifying
Compounds
5-azacytidine
Levofloxacin
Prednisone
Procaine
Suberohydroxamic Acid
Trimethoprim

Treatment
Concentrations (Fungi)
100 μM and 500 μM
500 μM and 1000 μM
500 μM and 1000 μM
200 μM and 400 μM
350 μM and 700 μM
500 μM and 1000 μM

Treatment Concentrations
(RI06-95)
100 μM and 500 μM
1 μM and 5 μM
--500 μM and 1000 μM
250 μM and 500 μM
0.1 μM, 1 μM, and 10 μM

Table 2: Treatment concentrations of each EM tested.
Extraction and Detection of Changes in Metabolite Formation
Frozen cells were thawed and then centrifuged to pellet cellular debris. A funnel
containing 20 micron filters were placed airtight on top of C18 sep-packs (Maxi-CleanTM
300 mg C18; Alltech Associates Inc., Deerfield, IL). The C18 sep-packs were then
placed on a vacuum manifold. Centrifuge supernatant was vacuumed through the seppacks, rinsed with deionized water to remove salts, and eluted with methanol. The liter
cultures of RI06-95 were extracted at different time points: 1 day, 2 days, and two liters 5
days post addition of trimethoprim. Two extraction methods were utilized for each liter
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of culture. 500 mL was extracted by liquid/liquid partitioning with ethyl acetate and 500
mL was extracted using XAD resin (Amberlite® XAD16, Sigma Aldrich).
The dried extracts were then analyzed by analytical high pressure liquid
chromatography (HPLC). HPLC was performed on a Hitachi Elite LaChrom system
consisting of a 2130 pump, L-2200 autosampler and a L-2455 diode array detector and
equipped with a C18 column (Sunfire C18 5μm, 2.1 mm x 150 mm column). HPLC
grade methanol (Pharmaco-AAPER; Brookfield, CT) and deionized water both
containing 0.1% trifluoroacetic acid (TFA) were used for the mobile phase (2 minutes
isocratic flow 5% MeOH, 16 minutes linear gradient to 100% MeOH, 6 minutes isocratic
100% MeOH; flow rate = 0.5 mL/min). Blanks of each EM were also analyzed using the
same gradient to allow for the identification of the EM peak in treated cell extracts.
Chromatograms of extracts from untreated cells were then compared to that of treated
cells and differences were noted.
Isolation and Structural Characterization of Induced Metabolites From RI-0695
An induced compound produced by RI06-95 in multiple small scale cultures was
isolated by semi-preparative HPLC using a C18 column (Phenomenex Luna C18 5 μm,
250 mm x 10 mm column). Methanol and deionized water both containing 0.1% TFA
were used for the mobile phase (3 minutes isocratic 40% MeOH, 14 minutes linear
gradient to 70% MeOH; flow rate = 2 mL/min). The isolated molecule was then dried in
vacuo.

Mass spectrometry data was obtained by direct infusion on a Q-Star Elite

(Applied Biosciences MDS) mass spectrometer equipped with a Turbo Ionspray source.
The isolated molecule was dissolved in DMSO and analyzed by H-NMR on an Agilent
500MHz spectrometer (Agilent; Santa Clara, CA).
8

RESULTS
South Pacific Gyre Fungi Treated with EM
The MIC was determined for each fungus to each of the EMs (See Appendix 1 for
list of MICs). Following suit of other previous studies in the literature, concentrations of
EM used during treatments were a tenth of the MIC. However, not all fungi had a clear
MIC with each EM. Many displayed morphological changes at lower concentrations.
With this observation in mind, concentrations up to half the MIC were used during the
treatment of fungi as it was hypothesized that altered morphology would lead to the
discovery of new chemistry.
Extracts from fungi treated with an EM were compared to both untreated controls
and blank runs containing only the EM used. Blank EM HPLC runs made it possible to
determine if a new peak found in an extract was a new metabolite rather than the EM or
breakdown product of the EM. Chromatograms from treated cells did not contain many
new molecules; however, several treatments did stimulate the production of some minor
peaks. Suberohydroxamic acid stimulated F53, F65, and F70 to produce new minor
peaks. Several molecules in treated cells of F17, F53 and F65 were decreased in relative
quantity or removed. More common than the creation of new molecules was the loss or
decreased abundance of some molecules found in treated cell extracts. Nearly all fungi
treated with the procaine displayed a decreased abundance of certain compounds and in
some cases the near complete absence of compounds in response to EM treatment.

9

Figure 1:Chromatographs from EM treated and untreated fungi. (Top) New compound
formation in response to SBHA treatment. Blue chromatogram represents F70 treated
with 350 µM of SBHA while the red is the untreated control. Note the new peak at 13.5
minutes. (Bottom) Removal of peak and two new peaks: Blue chromatogram represents
F53 treated with 200 µM of procaine while the red is the untreated control. Note the
decreased intensity of the peak at 20 minutes and the two new small peaks at 10 and 11
minutes. The large peak at 3.5 minutes represents the added procaine modifier.
New Molecules Induced by EM in RI06-95
The MIC for RI06-95 was determined for each EM used (See Appendix 1). RI0695 was then treated with each EM based off a tenth of the observed MIC. The MIC to
trimethoprim was unclear and the cells displayed morphological differences at all
concentrations despite no observed inhibition of growth.

Therefore three different

concentrations of trimethoprim were tested: 10 μM, 1 μM, and 0.1 μM.
During several small scale treatments, chromatograms from cells treated with
trimethoprim and 5-azacytidine displayed the production of an identical new peak
compared to untreated controls (See Figure 2). The creation of this peak was dependent
on the concentration of EM used. The concentrations of 10 μM and 1 μM trimethoprim
induced the production of the new metabolite; however, the 0.1 μM concentration
10

showed no effect on inducing the compound of interest. Also, the 100 μM 5-azacytidine
stimulated compound formation but not the 500 μM concentration. This molecule has
three UV maxima: 230 nm, 295 nm, and 330 nm. Due to the low concentration of
trimethoprim used, its respective peak was not observed in the HPLC chromatogram of
treated cells. 5-Azacytidine degrades in water and after five days of culturing. Thus, a
peak corresponding to 5-azacytidine is not observed in the HPLC chromatograms of
treated cells.

A)

B)
Figure 2: Treatment of RI06-95 with trimethoprim and 5-azacytidine induces the
production of a new compound with the same UV spectrum and HPLC retention time.
A) Chromatograms of untreated controls, 5-azacytidine 100 μM, and trimethoprim 1 μM
treated cells (top, middle, and bottom respectively). B) UV spectra of the induced
metabolite from both 5-azacytidine (left) and trimethoprim (right).
11

The molecule stimulated in response to trimethoprim and 5-azacytidine was
isolated via semi-preparative HPLC from several small scale extracts yielding 0.9 mg of
pure material. During semi-preparative HPLC, several compounds were observed with
similar UV spectra to that of the induced molecule indicating the presence of potential
analogs. Due to limited material, these potential analogs were not isolated, and only the
major peak was collected. Time of flight mass spectrometry (Q-Star Elite in positive ion
mode) revealed a single ion correspond to M+H at 362.1771 (See Appendix 2).
Fragmentation of the 362.1771 peak yielded fragments of 220.9899, 260.9843, and
317.9950 in positive ion mode.

Analysis 1H NMR data was inconclusive due to

insufficient material, leading to acquisition of poor spectra, and a potential contaminant
(See Appendix 3).
One liter-scale cultures treated with 1 μM trimethoprim did not result in
production of the previously mentioned new metabolite. However, the cultures did
produce an amicoumacin metabolite which was not present in the small scale cultures.
Amicoumacin A is a metabolite already known to be produced by RI06-95 and was
dereplicated by retention time and UV spectra (Li, 2012; Socha, 2008). In several repeats
of the small scale RI06-95 cultures, the treated cells responded similarly to that of the 1 L
upscale cultures.

Control cells lost the ability to produce amicoumacin; however,

amicoumacin production was restored when treated with either trimethoprim or 5azacytidine.
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Figure 3: EM induced amicoumacin from 25 mL small scale culture. (Left top)
Chromatogram of untreated control cells and (left bottom) trimethoprim 1 μM treatment
cells. (Right)UV spectra of the induced molecule with maxima at 247 nm and 314 nm.
DISCUSSION
New metabolite formation was observed in several fungi treated in this study.
However, the majority of peaks formed in response to EM in this study were relatively
minor compared to others in the extract. Of all the EM tested, suberohydroxamic acid
appeared to alter the epigenome of the most fungi treated. This finding correlates to
previous studies which also found that suberohydroxamic acid is one of the most active
compounds in altering the epigenome of fungi (Fisch, 2009; Cichewicz, 2010). Histones
play an extremely important role in the storage of DNA in fungi, and therefore it is
understandable that a HDAC inhibitor like suberohydroxamic acid was best at inducing
epigenetic changes.
Upon validating our technique for the induction of new peak formation in fungi,
the bacterium RI06-95 was tested.

Unlike fungi, bacteria lack histones and rely upon

other means to regulate gene transcription, one of the most important being the
methylation of DNA (Casadesús,2006). Therefore, it was hypothesized that if any EM
13

would induce the production of new compounds in bacteria through epigenetic changes it
would be one of the DNA methyltransferase inhibitors. The results observed during this
study confirmed this hypothesis. 5-Azacytidine, an EM which stimulated the production
of the new metabolite, inhibits DNA methyltransferase. Although trimethoprim does not
directly inhibit DNA methylation, it does prevent the formation of folic acid, which is a
cofactor used by enzymes as a methyl donor.

Suberohydroxamic acid, an HDAC

inhibitor which influenced the epigenome of the fungi used in this study the greatest,
displayed little affect on RI06-95.
The stimulated production of the same molecule by both trimethoprim and 5azacytidine poses questions as to the cause of the up-regulation and function of the
induced molecule. Was the molecule formed due to epigenetic regulatory mechanism
changes or was the molecule perhaps produced in response to a perceived microbial
threat? As trimethoprim is an antibiotic, RI06-95 may have sensed that it was under
attack by another organism and therefore produced its own secondary metabolites in
response. The restoration of the production of the antimicrobial amicoumacin by RI0695 in response to trimethoprim aligns to this theory. Interestingly though, a trend can be
seen in the literature as to the types of molecules produced in response to EM. The
majority of epigenetically induced compounds are either antimicrobials or toxins (Asai,
2012; Wang,2010; Wang, 2013; Williams, 2008; Zutz, 2013). Therefore, it may be have
been a combination of these two mechanisms at work in RI06-95.
The results from this study provide preliminary evidence that treatment of
bacteria with EM may be a useful technique in isolating additional bioactive molecules
beyond those produced under normal laboratory conditions.
14

A recent study in the

literature has investigated the plausibility of increasing secondary metabolite production
in bacteria through epigenetic modification (Wang, 2013). This study however was
inconclusive in regards to whether the observed changes in metabolite formation were
due to epigenetic modifying compound treatments or co-culturing. Extracts from neither
EM treated cells or co-cultured cells showed increased bioactivity in antimicrobial
assays, yet co-cultures treated with EMs were more bioactivity. Also, in mono-cultures
treated with EMs the researchers were also unable to distinguish whether the observed
changes in the LC-MS fingerprint were due to new compound formation or from
breakdown products of the EMs (Wang, 2013).

Reproducibility in our study posed a

difficulty as different cultures of the same strain of bacteria induced the production of
different compounds. With potential refinement of the methods and techniques used,
induction of specific metabolites may become more reproducible. Bacteria treated with
EM in both this study and the study performed by the Hamann group increased the
production of antimicrobials; restoration of amicoumacin production by RI06-95 and
increased production of antimicrobial quinolones and rhamnolipids from Pseudomonas
sp. co-cultures.

With the potential to discover new bioactive molecules, especially

antibiotics, the usage of EM should be expanded beyond their current focus on fungi.
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CHAPTER 2:
GENOME MINING AND BIOINFORMATIC ANALYSIS OF NATURAL
PRODUCT GENE CLUSTERS TO GUIDE COMPOUND ISOLATION FROM
THE ORGANISM BRADYRHIZOBIUM SP. BTAI1
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INTRODUCTION
Natural products are formed by organisms through a variety of molecular
pathways such as non-ribosomal peptide synthesis (Challis, 2004), polyketide synthesis
(PKS; Staunton, 2001), shikimate pathway (Maeda, 2012), and terpene synthesis
(Withers, 2007).

Each of these pathways consists of many enzymes that function

together to create the final compound. In microbes, the genes encoding for all the
enzymes responsible for the formation of a particular natural product are often clustered
together in the genome. Each enzyme in a synthetic pathway functions as part of an
assembly line, adding a new moiety to the molecule or catalyzing one or several reactions
before passing the molecule off to the next enzyme. The next enzyme may then add
another moiety or act as a catalyst for other reactions before passing off the molecule
again. Assembly continues in this fashion until the natural product is completely formed.
The order in which the enzymes function in the assembly line often matches the order in
which they are encoded in the genome, a concept known as colinearity (Fischbach, 2006).
By analyzing the DNA sequence and predicted amino acid sequence of each enzyme in a
natural product gene cluster, one can predict the functionality of each enzyme, and
therefore also make predictions of the overall structure of the secondary metabolite that
the gene cluster is responsible for generating(Bachmann, 2005; Li, 2009; Lautru, 2005).
With recent advances in gene sequencing technology, numerous organisms have
had their genomes sequenced. The sequences of many of these organisms are posted on
the National Center for Biotechnology Information (NCBI) webpage allowing for the
creation of a database of publically available genomes. This database represents a pool
of secondary metabolite data that can be analyzed for natural product gene clusters,
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thereby leading to the identification of secondary metabolite producing organisms. Many
organisms are sequenced for reasons other than determination of their biosynthetic
potential, and thus have been largely overlooked in regards to their secondary metabolite
production.

The

Secondary

Metabolite

Online

Repository

(SMOR;

www.secondarymetabolism.com) is a new tool that rapidly analyzes the well-curated
complete microbial genome sequences located on the NCBI Genome Database and flags
natural product gene clusters. Upon analysis by SMOR, many organisms not previously
studied for the synthesis of natural products have been found to contain numerous natural
product gene clusters. These organisms represent an untapped pool of potential novel
compounds.
Bacteria belonging to the genus Bradyrhizobium are photosynthetic Gramnegative bacilli possessing a singular flagellum. They are soil bacteria that are known
form symbiotic relationships with legumes (Willems, 2006).

Bradyrhizobium sp.

nodulate around root hairs and fix nitrogen in the soil for the plant, and in return, the
plant provides the bacterium with nutrients. To date, it is this symbiotic relationship
which researchers have focused their interest the most regarding Bradyrhizobium due to
potential agricultural implications (Zahran, 2001; Torres, 2011).

Four species of

Bradyrhizobium have now been sequenced in order to gain insight into the symbiotic
relationships these bacteria form with plants (Giraud, 2007; Kaneko, 2002; Okubo,
2012). The sequenced genomes are publicly available on NCBI. In this project, these
genomes were analyzed by SMOR for the presence of natural product gene clusters. The
species Bradyrhizobium sp. BTAi1 (BTAi1) was found to contain five natural product
gene clusters. Two of the five clusters were identified for the hypothesized production of
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potentially important bioactive molecules, two predicted lipopeptide antibiotics. As no
literature could be found regarding secondary metabolite isolation from BTAi1, this
organism attracted our attention as a prime candidate for the production of previously
overlooked secondary metabolites.
METHODS
Bioinformatic Analysis of Natural Product Gene Clusters:
Organisms with numerous natural product gene clusters were identified using
SMOR. A background literature search was performed for each organism identified this
way, and those that had not undergone secondary metabolite isolation studies were noted.
Gene clusters were then analyzed using SMOR, Pfam (Punta, 2012), BLAST, ClustalW2
(Larkin, 2007), and NRPSpredictor2 (Rottig, 2011) in order to predict the structure of the
metabolite formed by the cluster.

The SMOR interface allows for the rough

determination of the order in which enzymatic reactions take place. It also provides the
predicted primary amino acid sequence for every gene in the cluster. These sequences
can then be put in several analytical programs in order to determine the functionality of
each gene product. Pfam allows for the identification of protein motif regions that may
give clues to the functional motifs of the gene (Punta, 2012). NRPSpredictor2 analyzes
NRPS gene motifs and predicts which amino acid will be incorporated into the secondary
metabolite (Rottig, 2011). ClustalW allows for the comparison of a gene within the
cluster to genes with known functionality using sequence alignment algorithms and
phylogenetic tree formation (Larkin, 2007). By doing so, it is possible to determine if a
gene is functionally similar to a comparator. After analyzing the gene cluster of several
organisms using the previously mentioned bioinformatics tools and performing
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background literature searches, the organism BTAi1 was selected for this study and was
purchased from the American Type Culture Collection (ATCC).
Culturing and Extraction:
Dry spores of BTAi1 were received from the ATCC and were transferred to 5 mL
of a medium similar to the recipe used by the ATCC (2.5g/L glutamate, 2 g/L yeast
extract, 0.66 g/L K2HPO4, 0.05 g/L NaCl, 0.1 g/L MgSO4*7H2O, 0.04 g/L CaCl2, 0.004
g/L FeCl2·4H2O) and grown at 30 °C shaking at 150 RPM for 5 days. The cell culture
was then further expanded by transferring 2 mL into 50 mL of sterile medium. The
remaining broth from the 5 mL culture was then used to create cryovials: 0.5 mL culture
medium was added to 1 mL of 50% sterile filtered glycerol and stored at -80°C. The 50
mL culture was then grown for two weeks shaking at 150 RPM at 30°C.
As BTAi1 is a photosynthetic organism, 2 mL of the 50 mL culture mentioned
above was placed into two flasks containing 50 mL of fresh media; one covered in foil
and one exposed to light. These cultures were grown for one month at 30 °C while
shaking at 100 RPM under a growth light. The cultures were centrifuged at 2000 RPM
for 4 minutes. Supernatant was passed through a 20 micron filter and then a C18 seppack (Maxi-CleanTM 300 mg C18; Alltech Associates Inc., Deerfield, IL) via vacuum.
The sep-pack was rinsed with 2 mL of deionized water to remove salts. The cell pellet
was resuspended in 5 mL methanol, vortexed, and then centrifuged again at 2000 RPM
for 4 minutes. The methanol was then passed through the sep-pack, collected, and dried
in vacuo. Each extract was brought to 10 mg/mL in methanol and analyzed by high
pressure liquid chromatography (HPLC).

HPLC was performed on a Hitachi Elite

LaChrom system consisting of a 2130 pump, L-2200 autosampler and a L-2455 diode
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array detector and equipped with a C18 column (Sunfire C18 5μm, 2.1 mm x 150 mm
column). Methanol and deionized water both containing 0.1% TFA were used for the
mobile phase (Isocratic 5% MeOH for 2 minutes, linear gradient to 100% MeOH over 16
minutes, isocratic 100% MeOH for 6 minutes).
A 50 mL culture was created and grown for two weeks shaking at 150 RPM at
30°C. Liter cultures were then started by transferring 2 mL from the 50 mL culture into
five flasks containing 1 L of sterile medium. Cells were grown for over a month at 25 °C
while shaking at 150 RPM. The cultures were extracted using ethyl acetate partitioning
and dried in vacuo.
Compound Isolation:
Crude extract was adsorbed to C18 resin and fractionated by CombiFlash medium
pressure liquid chromatography (MPLC) equipped with a C18 column (RediSep SF High
Performance Gold 50 g C18 column; Teledyne, Lincoln, NE). A mobile phase of water
and methanol was used (Isocratic 5% MeOH for 5 minutes, linear gradient to 100%
MeOH over 30 minutes, isocratic 100% MeOH for 10 minutes; flow rate = 40 mL/min).
Compound isolation was guided by disk diffusion assays against methicillinresistant Staphylococcus aureus (ATCC 25923; MRSA). MRSA cultures were grown
overnight at 37 °C on tryptic soy agar (DifcoTM Tryptic Soy Agar; Becton, Dickinson and
Co, Sparks, MD). Select colonies were picked, inoculated into 10 mL of tryptone soy
broth (BactoTM Tryptic Soy Broth, Soybean-Casein Digest Medium; Becton, Dickinson
and Co, Sparks, MD) and grown for 24 h at 37 °C. Crude extract (5 mg/disk and 0.5
mg/disk) and fractions (0.150 mg/disk) were dissolved in methanol, loaded onto paper
disks, and then dried at ambient temperature. MRSA was swabbed from the broth
21

cultures onto tryptic soy agar plates and disks were then arranged onto the plate. For
each disk diffusion assay, methanol blank and ciprofloxacin disks were used as negative
and positive controls. A control disk prepared by loading extract from sterile media (2.5
mg/disk) was also tested. Initially, the ciprofloxacin controls contained 0.625 mg/disk.
Due to large zones of inhibition, later experiments used 0.150 mg/disk of ciprofloxacin.
The bioactive fraction JSc1-95-2 was found to contain two major peaks. These
peaks molecules were isolated via semi-preparative HPLC. A C18 column (Phenomenex
C18 5 μm, 10mm x 250 mm) was used with a mobile phase of methanol and water both
containing 0.1% TFA (Isocratic 5% MeOH for 2 min, linear gradient to 70% MeOH over
11 min, linear gradient to 100% MeOH over 3 min, isocratic 100% MeOH for 2 min;
flow rate of 5 mL/min).
Structural Characterization of Isolated Fractions:
Mass spectrometry data was obtained by direct infusion on a Q-Star Elite
(Applied Biosciences MDS) mass spectrometer equipped with a Turbo Ionspray source.
Both JSc1-95-2-2 and JSc1-95-2-3 were dissolved in DMSO-d6 in a nitrogen atmosphere
and analyzed by 1H NMR on an Agilent 500 MHz spectrometer (Agilent; Santa Clara,
CA).
RESULTS AND DISCUSSION
Natural Product Gene Cluster Analysis
Review of the SMOR database and background literature search led to the
selection of BTAi1 for this study. BTAi1 was found to have five natural product gene
clusters: a potentially broken cluster, a polyketide synthesized by an iterative type III
PKS, a tetrapeptide, and two potential lipopeptide antibiotics (See Figures 4-8). BTAi1
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was originally sequenced by researchers investigating its ability to fix soil nitrogen. No
biosynthetic studies had been previously done with BTAi1 in pure culture. However,
several studies previously examined the effect of BTAi1 on the production of
phytoestrogens by yeast expressing soybean chalcone isomerases (Ralston, 2005).

The

lack of biosynthetic research, ability to easily acquire the organism from the American
Type Culture Collection (ATCC), and presence of the two potential lipopeptide
antibiotics clusters made BTAi1 a potentially ideal candidate for this study.
The first natural product gene cluster in BTAi1 contains only one gene that may
produce secondary metabolites. This gene is a Type III Polyketide Synthase (PKS) that
is 1052 bases long. Numerous forms of Type III PKS exist which utilize different
substrates as building blocks. In order to predict the structure of the potential metabolite,
a phylogenetic tree was created from the primary protein sequences of numerous forms of
Type III Polyketide Synthases via ClustalW (BLOSOM alignment, gap extension penalty
= 0.1, gap opening penalty = 10). Included in the tree were two alkylresorcinol synthases
(srsA

Streptomyces

fulvissimus,

AGK81780.1;

srsA

Streptomyces

griseus,

YP001821984.1), three dihydroxyphenylacetylglycine synthases (dpa Amycolatopsis
orientalis, CCD33159.1; dpgA Streptomyces toyocaensis, AAM80548.1;
Actinoplanes

teichomyceticus,

CAE53371.1),

three

alkylpyrone

dpgA

synthases

(gcs

Streptomyces coelicolor, 3V7I_A; PKS18 Mycobacterium tuberculosis, Q7D8I1.1; arsC
Azotobacter vinelandii strain DJ, ACO79120.1), three tetrahydroxynaphthlene synthases
(rppA

Streptomyces

griseus,

YP001828132.1;

rppA

Streptomyces

lividans,

BAB91445.1; rppA Streptomyces antibioticus, BAB91443.1), two octaketide synthases
(octaketide synthase Aloe arborescens, AAT48709.1; octaketide synthase Hypericum
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perforatum, ACF37207.1), two valerophenone synthases (valerophenone synthase
Humulus

lupulus,

BAA87923.1),

two

ACM17227.1;
acridone

valerophenone

synthases

(acridone

synthase
synthase

Psilotum
Ruta

nudum,

graveolens,

CAC14058.1; acridone synthase Huperzia serrata, ABI94386.1), one benzalacetone
synthase (benzalacetone synthase Rheum palmatum, AAK82824.1), and two chalcone
synthases (chalcone synthase Medicago sativa, AAB41559.1; chalcone synthase Glycine
max, AAB01004.1). As expected, the forms of Type III PKS found in plants (octaketide
synthases, valerophenone synthases, acridone synthases, benzalacetone synthases,
chalcone synthases) grouped together. Also, the multiple sequences used for each form
of Type III PKS grouped amongst themselves except for the alkylpyrone PKS18
sequence from Mycobacterium tuberculosis. The identified Type III PKS in BTAi1
showed the most homology to the alkylresorcinol synthase protein sequences. Other
nearby genes found in the gene cluster encode for a DNA lysase, an isoprenylcysteine
carboxyl methyltransferase domain, and a putative multidrug resistance protein.
Therefore, this molecule is predicted to be a relatively small polyketide molecule,
possibly an alkylresorcinol derivative, containing potential methylation.

Due to the

proximity of the multidrug resistance protein to the cluster, it is possible this compound is
secreted by the cell into the surrounding environment.
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Figure 4: (Top) BTAi1 cluster 1 layout and (bottom) Type III PKS phylogenetic tree.
(Top) DL = Predicted DNA Lysase, THNS = Predicted Type III PKS, MT = Predicted
Methyltransferase, MDR = Predicted Multi-Drug Resistance Transporter. (Bottom)
Phylogenetic tree created from protein sequences of different forms of Type III PKS and
the identified Type III PKS in BTAi1.
The second natural product gene cluster is predicted by SMOR to encode for a
secondary metabolite consisting of nine amino acids. Upon further analysis of the genes
in the cluster, the adenylation domain predicted by SMOR in the loading unit was instead
found to be a fatty acyl-AMP ligase (e-value = 0+00) by the conserved domain database.
The NRPS Predictor 2 program predicted the sequence of the eight amino acids as AspGly-Phe-Gly-Leu-Glu-Gly-Leu. This cluster includes three epimerization domains which
25

may be responsible for altering the stereochemistry of the aspartic acid, central leucine
and glutamic acid residues.
leucines.

All amino acid predictions are strong except for both

Nearby genes include ornithine oxidases and therefore the leucines may

actually be oxidized ornithines.

This natural product appears to belong to the class of

molecules known as cyclic lipopeptides; a class of antimicrobials known to be active
against MRSA. Another gene cluster in BTAi1 lipopeptide is annotated for its similarity
to arthrofactin synthetase. Arthrofactin is a partially cyclic lipoptide with aspartic acid
and leucine as the amino acid residues adjacent to the fatty acyl chain (Morikawa, 1993),
just like the metabolite for this second gene cluster. The location of the neighboring
leucine and aspartic acid residues in the predicted cluster two metabolite are reversed
compared to arthrofactin; leucine on the C-terminal and aspartic acid on the N-terminal
of the peptide chain . Therefore this metabolite is predicted to cyclize in the same way as
arthrofactin. The genes bordering the cluster are all predicted as hypothetical proteins
except for one which is predicted to be a pyoverdine ABC transporter permease/ATPbinding protein. As both pyoverdine and the predicted metabolite are cyclized NRPS
molecules it is probably that this compound is secreted outside the cell as would be
expected for an antibiotic. Over 13,000 bases away there is also a glycosyltransferase
which may indicate, though unlikely due to the distance away from the cluster, that the
metabolite may be glycosylated.
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Figure 5: BTAi1 cluster 2 layout and structures of the predicted metabolite and
arthrofactin. (Top) Layout of the second BTAi1 natural product gene cluster. A =
Adenylation domain, T = Carrier protein, C = Condensation domain, E = Epimerization
domain, TE = Thiol Esterase, ABC = Predicted ABC transporter, FAAL = Fatty AcylAMP. (Bottom Left) Predicted structure of the cluster two metabolite. R-group is
predicted to be a fatty acid chain. (Bottom right) Structure of arthrofactin. The
metabolite from the second natural product gene cluster is predicted to cyclize in the
same fashion as arthrofactin.

The third natural product gene cluster in BTAi1 appears to be responsible for the
synthesis of a tetrapeptide connected to a formyl unit. This formyl unit may serve as an
attachment point for other molecules or to cyclize the metabolite. The predicted amino
acid sequence for the natural product is Ser-Orn-Orn-β-Ala.

The β-Ala was a peak

prediction and could potentially be Asp, Asn, Glu, Gln, or Aad (aminoadipic acid)
instead. The second ornithine is predicted to be epimerized and contain stereochemistry
different from the previous ornithine.
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Figure 6: BTAi1 cluster 3 layout and structure of the predicted metabolite. (Top)
Layout of the third BTAi1 natural product gene cluster. A = Adenylation domain, T =
Carrier protein, C = Condensation domain, E = Epimerization domain, TE = Thiol
Esterase, FT = Formyltransferase. (Bottom) Predicted structure of the cluster three
metabolite.
The fourth natural product gene cluster identified in BTAi1 has several interesting
properties. First of all, it has an extra condensation domain situated at the end of the
cluster without an adenylation domain following it. Secondly, this gene cluster lacks a
thiolesterase domain. A putative alkanesulfonate monooxygenase gene neighbors the
cluster and may be responsible for removing the secondary metabolite from the final
carrier protein. However, the alkanesulfonate monooxygenase is at the beginning of the
gene cluster and not at the end where thiolesterase domains normally reside. Where the
TE domain should reside is an acyl carrier protein phosphodiesterase (ACPP). The
ACPP may also be responsible for the release of the molecule. The first adenylation
domain predicted by SMOR was later identified instead as a fatty acyl-AMP ligase. It
was identified as being similar to the fatty acid CoA ligase called Fum10p (e-value =
3.01x10-137). Fum10p has been determined to act like an adenylation domain responsible
for the ester side groups found in the class of compounds known as fumonisins
(Huffman, 2010). The second adenylation domain was weakly predicted to incorporate a
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β-Ala. Other potential amino acids that may be used as substrates instead include asp,
asn, glu, gln, and aad. Based on the above analysis, the metabolite produced by this gene
cluster appears to be either used as a building block for other molecules or the gene
cluster is broken and does not produce any metabolites.

Figure 7: BTAi1 cluster 4 layout and structure of the predicted metabolite. (Top)
Layout of the fourth BTAi1 natural product gene cluster. A = Adenylation domain, T =
Carrier protein, C = Condensation domain, ACPP = predicted putative acyl carrier
protein phosphodiesterase, SMO = predicted alkanesulfonate monooxygenase. (Bottom)
Predicted structure of the cluster four metabolite.
The final natural product gene cluster identified by SMOR in BTAi1 consists of
three genes encoding fourteen NRPS adenylation domains. Interestingly, there appears to
be no loading domain. Large gaps exist between the gene cluster and other adjacent
genes. Genes encoding transcription factors are 10kb away from cluster, and it is unclear
if they may affect the transcription of the cluster. The predicted sequence of the 14
amino acid metabolite by NRPS Predictor2 is Leu-Ser-Ala-Val-Val-Ala-Ser-Leu- LeuThr-Ser-Ser-Val-Leu. All predictions in the metabolite were strong except for both
alanines which may vary and be either serines or threonines. All three genes in this
cluster were found to be arthrofactin synthetase/syringopeptin synthetase C-related non
ribosomal peptide synthetases.

Arthrofactin, like this predicted molecule, contains
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numerous leucines and amino acids containing hydroxyl groups. This cluster varies from
arthrofactin though as it does not contain any genes that appear to incorporate a lipid
component, however, the numerous hydroxyl groups may serve as attachment points.
The predicted molecule also contains an additional two amino acid residues compared to
arthrofactin.

Figure 8: BTAi1 cluster 5 layout and structure of the predicted metabolite.
(Top) Layout of the fourth BTAi1 natural product gene cluster. A = Adenylation domain,
T = Carrier protein, C = Condensation domain, TE = Thiol Esterase. (Bottom)
Predicted structure of the uncyclized cluster four metabolite.
Cell Culture and Extraction Yield
BTAi1 is a photosynthetic organism. To determine if light would alter secondary
metabolite formation, two small scale cultures of BTAi1 were grown; one under a growth
light and the second wrapped in tin foil. After C18 sep-pack adsorption and elution with
methanol, broth extracts from light and dark treatments were compared by analytical
HPLC. Overlays of the two chromatographs (See Figure 9) showed only the difference
of one extra peak produced in the cells grown in the dark. With this is mind, upscale
cultures were grown without growth lights. Cultures maintained under light and darkness
grew at the same relative rate. However, the growth curve observed was much slower
than previously mentioned in existing literature; cultures took over thirty days to show
full growth despite previous reports stating seven days (Wettlaufer, 1992).
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Figure 9: Overlay of the extracts from BTAi1 cultures grown under light and in
darkness. The cells grown in the dark (blue) displayed an additional peak at 9 minutes
compared to the cells grown under lights (red).
When BTAi1 was cultivated in 1 L broth cultures, slow growth was still observed
and cultures needed more than a month to show sufficient growth to warrant extraction.
The cells did not grow dispersed within the medium but instead in clumps on the flask
just above the level of the medium when shaking. This growth pattern was observed in
the small scale cultures but not as noticeably as in larger scale. This observation may be
due to the fact that in its natural environment, BTAi1 grows in the soil around root
nodules.

Extraction of the medium via liquid/liquid partitioning with ethyl acetate

yielded a low quantity of material. A total of 172.3 mg of crude extract was obtained.
Isolation Chemistry and Structure Characterization
Disk diffusion assay against MRSA with the crude extract showed a zone of
inhibition with the higher concentration disk. Fractionation of the crude extracted by
reverse phase MPLC generated nine fractions. In order to attempt to locate the two
predicted lipopeptide antibiotics among these fractions, isolation was guided by disk
diffusion assay against MRSA. One fraction, JSc1-95-2, was found to have activity
against MRSA and another fraction, JSc1-95-4, was found to have partial activity.
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Figure 10: Disk diffusion assay of BTAi1 MPLC fractions against MRSA. Fraction
JSc1-95-2 (disk labeled 7-10 corresponding to MPLC tube collections 7-10) showed a 14
mm zone of inhibition. Fraction JSc1-95- 4 (labeled 17-21; lower left disk on right plate)
displayed a weaker, but still evident, zone of inhibition.
JSc1-95-2 consisted predominantly of two peaks when analyzed by reverse phase
C18 analytical HPLC. These two compounds, denoted JSc1-95-2-2 and JSc1-95-2-3,
were subsequently isolated by semi-preparative HPLC with final yields of 0.3 mg and 1
mg respectively (See Appendix 4). Unfortunately, isolates were not pure and with
minimal material, structure elucidation of the compounds was not possible. Enough
material was present however to allow for the initial characterization of these molecules.
Only 0.3 mg of JSc1-95-2-2 was isolated and analysis by mass spectrometry
indicated that it was not entirely pure. The major ion of JSc1-95-2-2 was observed best
in negative ion mode at 363.4843 (See Appendix 5). The UV spectrum of JSc1-95-2-2
contains a maxima at 328 nm. These pieces of data indicate that JSc1-95-2-2 is a small
highly conjugated molecule. The only identified natural product gene cluster in the
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BTAi1 genome that could form a molecule of this size is the predicted tetrapeptide.
However, the predicted tetrapeptide structure is inconsistent with the observed UV
spectra.
Analysis of fraction JSc1-95-2-3 by mass spectrometry did show the presence of
ions residing near the masses off the predicted lipopeptides with the largest at 1123.0052
in negative ion mode (See Appendix 6). A mass fragmentation pattern (1032.4199,
1046.3720, 1060.3140, 1074.2662) in negative ion mode indicated the sequential loss of
methylenes which could correlate to the alkyl chain of the predicted lipopeptide. MS/MS
analysis of the 499.2464 peak in negative ion mode yielded only one product ion of
113.9627 which corresponds to the mass of aspartic acid (See Appendix 7). In the
prediction of the cluster two metabolite, the amino acid residue adjacent to the fatty acyl
chain was predicted to be an aspartic acid. Therefore, the potential mass of the acyl chain
may be 385.2837. The loss of methylene fragmentation pattern potentially indicative of
the alkyl chain is also present in the 300 mass range (297.8745, 311.8536, 325.8316,
339.8069) in negative ion mode. Currently the exact mass of the fatty acyl chain remains
unclear as does the connectivity of the acyl chain to the peptide. Identification of the
peptide sequence by MS/MS fragmentation studies was unclear and challenged by the
fact that the peptide is predicted to be cyclized and not linear. The UV spectrum of JSc195-2-3 has a maximum at 284 nm which may be resultant of the predicted phenylalanine
residue in the cluster two metabolite. Unfortunately due to low quantity of material and
presence of impurities, NMR analysis was inconclusive (See Appendix 8 and 9).
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CONCLUSION
Preliminarily, it appears promising that BTAi1 is creating lipopeptide antibiotics
as predicted based on observed antimicrobial bioactivity and mass spectrometry data.
Unfortunately due to long culturing times and low extraction yields, purification and
structure elucidation of the bioactive molecules was not possible at this time. Culturing
times of BTAi1 was much greater than previously stated in the literature.

As BTAi1 is

soil microbe, one potential way to optimize growth may be to grow the organism on solid
agar surfaces rather than broth in order to best mimic the organism’s natural environment.
Should liquid cultures be repeated, the inclusion of glass beads should be used to keep the
cells in the media rather than clumping to the sides of the flask at the media surface line.
Alterations of media constituents could also be performed which mimic those found
naturally in the soil. Extraction methodology also requires optimization as the solvent
partitioning with ethyl acetate yielded less than 30 mg per liter culture. Extraction using
a resin may be preferable.
With future optimization of growth conditions and extraction methodology,
elucidation of the structure of the responsible antimicrobial compounds may be
conceivable. With higher amounts of starting material, isolation of the other predicted
molecules may be explored as well. As drug resistant organisms continue to become ever
more prevalent, discovery of new antimicrobials is of the utmost importance. Genome
mining and identification of organisms overlooked for secondary metabolite production
may pose as a practical technique for the isolation of these clinically needed molecules.
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Appendix 1: MIC values of each microorganism tested to each epigenetic modifying
compound. Values listed with an asterisk (*) were the highest concentrations that visibly
altered cell morphology though did not inhibit growth. DMSO control was test as DMSO
was required to fully dissolve both prednisone and trimethoprim. Listed percent values
are vol/vol.
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+TOF Product (362.0): 0.132 to 0.165 min from Sample 2 (EM peak 362 ms.ms ce 40) of EM peak 362 ms.ms ce 40.wiff
a=3.59577000056934680e-004, t0=-6.01277179989930220e+000 (Turbo Spray)

Max. 84.7 counts.
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Appendix 2: MS and MS/MS data in positive ion mode for the molecule produced by
RI06-95 in response to 5-azacytidine and trimethoprim.
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Appendix 3: 1H-NMR spectrum of the molecule produced by RI06-95 in response to 5azacytidine and trimethoprim. Spectrum obtained in DMSO.
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Appendix 4: (Top) HPLC-DAD analysis from the semi-preparative HPLC of JSc1-95-2
yielding 0.3 mg of JSc1-95-2-2 (11 minutes) and 1 mg of JSc1-95-2-3 (12 minutes).
(Bottom left) UV spectrum of JSc1-95-2-2 with a maximum at 328 nm. (Bottom right)
UV spectrum of Jsc1-95-2-3 with a UV maximum at 284 nm.
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-TOF MS: 0.199 min from Sample 1 (JSc1-95-2-2 neg ion) of JSc1-95-2-2 neg ion.wiff
a=3.58276360280523390e-004, t0=-2.21630431380759550e+002 (Turbo Spray)

Max. 1.5e4 counts.
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3560

Max. 3560.1 counts.

118.0850

3400
3200
3000
2800
2600

In te n s ity , c o u n ts

2400
2200
2000
1800
1600
201.0984

1400

254.0439

1200
1000
221.0160

800

242.9970

205.0639

600
107.0330

168.9933
223.0795

400

409.1693
200
0
100

337.0602

125.0030
120

140

160

180

200

220

240

260

280

300

320

340
m/z, Da

507.1815
360

380

400

420

440

460

480

500

525.1912

520

540

560

Appendix 5: Mass spectroscopy of JSc1-95-2-2 in negative (top) and positive (bottom)
ion modes.
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-TOF MS: 0.065 to 0.215 min from Sample 1 (JSc1-95-2-3 neg ion) of JSc1-95-2-3 neg ion.wiff
a=3.58276360280523440e-004, t0=-2.21630431380759550e+002 (Turbo Spray)

Max. 1295.7 counts.
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a=3.59577000056934580e-004, t0=-6.01277179989930220e+000 (Turbo Spray)
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Appendix 6: Mass spectroscopy of JSc1-95-2-3 in negative (top) and positive (bottom)
ion modes.
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-TOF MS: 0.082 to 0.215 min from Sample 1 (JSc1-95-2-3 neg ion) of JSc1-95-2-3 neg ion.wiff
a=3.58276360280523440e-004, t0=-2.21630431380759550e+002 (Turbo Spray)

Max. 1289.4 counts.
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Appendix 7: (Top) Ions observed during TOF-MS analysis in negative ion mode of JSc195-2-3 which indicate the loss of methylenes. (Bottom) JSc1-95-2-3 MS/MS of 499.2464
peak in negative ion mode. 113.9627 correlates to the mass of aspartic acid. In the
prediction of the cluster two metabolite the amino acid residue adjacent to the fatty acyl
chain was predicted to be aspartic acid.
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Appendix 8: 1H-NMR spectrum of JSc1-95-2-2 in DMSO-d6. Due to insufficient
material, solvent and water peaks drowned out the signal from the sample.
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Appendix 9: 1HNMR spectrum of JSc1-95-2-3 in DMSO. Two molecules can be
observed: one abundant and the other near baseline. The more abundant molecule is not
the molecule corresponding to the predicted lipopeptide.
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